logo Creation made simple
Beautifully designed
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut convallis tempor orci vitae vehicula. Aliquam in ullamcorper lacus.
Follow & share
Search:
Infallible Pharma | ATRAFLIP-C INJECTION
21016
portfolio_page-template-default,single,single-portfolio_page,postid-21016,edgt-core-1.0.1,ajax_fade,page_not_loaded,,hudson-ver-1.8, vertical_menu_with_scroll,smooth_scroll,side_menu_slide_from_right,blog_installed,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

ATRAFLIP-C INJECTION

ATRAFLIP-C INJECTION


Brand Name : Atraflip-C


Generic Name : Cisatracurium Besylate Injection USP 2mg/ml


Pack Size : 5 ml Ampule


Dosage Form : Injection


Strength : 2mg/ml


Therapeutic indications : Cisatracurium is indicated for use during surgical and other procedures in adults and children aged 1 month and over. Cisatracurium is also indicated for use in adults requiring intensive care. Cisatracurium can be used as an adjunct to general anaesthesia, or sedation in the Intensive Care Unit (ICU) to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation.


Pharmacotherapeutic group : neuromuscular blocking agent


ATC code : M03AC11


Pharmacodynamic properties : Cisatracurium is an intermediate duration, non depolarising benzylisoquinolinium skeletal muscle relaxant.
Clinical studies in man indicated that this medicinal product is not associated with dose dependent histamine release even at doses up to and including 8 x ED95.
Cisatracurium binds to cholinergic receptors on the motor end-plate to antagonise the action of acetylcholine, resulting in a competitive block of neuromuscular transmission. This action is readily reversed by anti-cholinesterase agents such as neostigmine or edrophonium.

Date

February 15, 2022

Share